PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 24, 2025Sakarya Üniversitesi Holistik Sağlık DergisiOpen Access

The Role of Liposomal Delivery Systems in the Treatment of Triple Negative Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

HTHava TaslakBYBurhanettin YalçınkayaZEZeliha Eskin

Discussion

Loading...

Member takes

Overview

Assessment of liposomal drug delivery systems addresses therapeutic resistance in triple-negative breast cancer, suggesting novel targeted therapies.

Key Points

  • Liposomal delivery systems improved therapeutic success in multiple TNBC models, indicating potential for clinical use.
  • Approximately 20% of breast cancer cases are triple-negative, with high rates of treatment resistance and recurrence.
  • Surface modifications like PEGylation and antibody conjugation enhance drug bioavailability and targeting in TNBC treatment.
  • Standardized production protocols are crucial for the successful translation of liposomal therapies into clinical settings.

Cite This Study

Taslak et al. (2025) studied this question.

synapsesocial.com/papers/68d6d8978b2b6861e4c3ebcchttps://doi.org/10.54803/sauhsd.1728842
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Advancements in Lipid Nanotechnology for the Treatment of Triple-Negative Breast Cancer: Mechanistic Insights and Future Prospects2026
  2. 2Enhancing the Anticancer Efficacy of Polyphenols Through Lipid‐Based and Polymeric Nanoparticle Delivery Systems in Triple‐Negative Breast Cancer (TNBC)2026
  3. 3Tailored Liposomal Nanocarriers for Precision Breast Cancer Therapy2026 · 1 citations
  4. 4Advances in nanoparticle-based doxorubicin delivery: precision strategies for targeted treatment of triple-negative breast cancer2025 · 17 citations
  5. 5Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple‐negative breast cancer2024 · 19 citations